Recently, Reguiaï and colleagues performed a retrospective study on a cohort of 20 HS patients (in whom at least one anti-TNF-α treatment failed or was not tolerated) treated with secukinumab (12 females and 8 males). This evidence concerns the gene TNF and histiocytic sarcoma.